Article
The Pharmacogenetic Rescue of Side-Lined Anticancer Drugs to the Front-Line: Gefitinib as a Case Example.
The Annals of pharmacotherapy - 1 Feb 2011
Li-Wan-Po Alain, Farndon Peter A, Kobayashi Susumu, Mitsudomi Tetsuya, Potter Vanessa A
Abstract excerpt
OBJECTIVE: To illustrate the increasing importance of pharmacogenetics in drug development and clinical practice through a critical analysis of the validation and licensing of gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, as a treatment for non-small cell lung cancer (NSCLC). DATA SOURCES: Journal articles and the "grey" literature were identified through a systematic search of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.